Evelyn Reynolds is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 36 publications with 261 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fennec Pharmaceuticals, Inc.Program year20242 payments
- GlaxoSmithKline, LLC.Program year20225 payments
- AstraZeneca Pharmaceuticals LPProgram year20224 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
78.9%Opioid Agonist35.5%Oxycodone-Acetaminophen100%Part D≥62 patientsNonsteroidal Anti-inflammatory Drug26.6%Ibuprofen100%Part D≥45 patients+ 2 more classes in this area
Metabolism & gastrointestinal
10.5%Serotonin-3 Receptor Antagonist10.5%Ondansetron Hcl100%Part D≥21 patientsGenitourinary & hormones
5.9%Estrogen5.9%Estradiol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: a prospective observational study
European Journal of Surgical Oncology
2026 - Lymphovascular Space Invasion in Stage I Endometrial Cancer: Does Quantity Matter?
International Journal of Gynecological Cancer
2026 - Delays to initial evaluation drive socioeconomic care disparities in endometrial cancer
Gynecologic Oncology Reports
2026 - ONCOLOGIC OUTCOMES OF THE SENTINEL LYMPH NODE MAPPING ALGORITHM IN SURGICALLY STAGED AGGRESSIVE ENDOMETRIAL CANCER ACCORDING TO HISTOLOGIC SUBTYPE: A RETROSPECTIVE STUDY
International Journal of Gynecological Cancer
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Bernard Gersh, PhD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
S. Vincent Rajkumar, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”